Back to today’s briefing

Story perspectives

Myriad Genetics Downgraded: Price Target Cut to $14

3/2/2025

26 2

Summary

Myriad Genetics Downgraded

Myriad Genetics (NASDAQ:MYGN) faced a setback as StockNews.com downgraded its rating from "buy" to "hold." Analysts are adjusting their expectations, with Piper Sandler slashing the price target to $14.00. Currently trading at $10.73, the company, valued at $976.81 million, is a key player in genetic testing and precision medicine for cancer.

Summary

Natera Shares Decline

Natera, Inc. (NASDAQ:NTRA) experienced a 5.5% drop in shares held by Bank of New York Mellon Corp, now totaling 958,684 shares worth $151.76 million. Despite this, the stock remains robust at $155.59, with analysts optimistic, offering a "Moderate Buy" rating and a promising price target of $172.69, underscoring the growing demand for its genetic testing services.

History

Historical Context

Myriad Genetics' stock downgrade echoes the 2015 Precision Medicine Initiative, which aimed to revolutionize genetic testing and personalized medicine. As advancements in genomics accelerate, companies face market pressures and investor skepticism, similar to the turbulence experienced during the early days of biotechnology in the late 1990s.

1 of 3

Myriad Genetics Downgraded

Myriad Genetics (NASDAQ:MYGN) faced a setback as StockNews.com downgraded its rating from "buy" to "hold." Analysts are adjusting their expectations, with Piper Sandler slashing the price target to $14.00. Currently trading at $10.73, the company, valued at $976.81 million, is a key player in genetic testing and precision medicine for cancer.

1 / 3